REVLIMID® (lenalidomide) in combination with a rituximab product is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). REVLIMID in combination with a rituximab product is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

PHASE III AUGMENT TRIAL OVERVIEW

REVLIMID® (lenalidomide) + rituximab (R2) vs rituximab in previously treated follicular and marginal zone lymphoma1

The first chemotherapy-free FL and MZL relapse treatment. Explore the clinical data.

Female HCP and Male Patient
Female HCP and Male Patient
Vial Icon

Patients in the AUGMENT trial were randomly assigned (1:1) to REVLIMID + rituximab or placebo + rituximab.1

Learn More About Trial Design
Book Icon

The primary endpoint of the AUGMENT trial was progression-free survival.2,18

Explore the Primary Endpoint
Checklist Icon

Both secondary and exploratory endpoints were also evaluated in the AUGMENT trial.2,18

See the Secondary Endpoints